Building on our discovery that JAK/STAT overactivation is associated with disease severity in murine and human malaria, we next evaluated whether pharmacological inhibition of JAK/STAT signaling with ruxolitinib could reverse the lethal phenotype in infected GRiKO mice. Here, SOAT1 is linked to malaria.